Considering that the conventional treatment of advanced stage pancreatic cancer can result in as little as a 1% 5-year survival rate, new preclinical research on a liposomal turmeric extract that inhibits pancreatic tumor growth by 42% is all the more amazing.
A promising new study published in the journal Anticancer Research, a peer-reviewed medical journal published by the International Institute of Anticancer Research, reveals a unique turmeric extract known as liposomal curcumin may provide an ideal chemotherapy alternative in the treatment of highly lethal pancreatic cancers.
Curcumin is the primarly polyphenol in turmeric, and has been the subject of extensive research demonstrating its ability to kill cancer cells, with over 1,500 studies available to view on Greenmedinfo.com relevant to over 100 distinct cancer types, including 24 studies demonstrating its anti-pancreatic cancer properties.
Liposomal curcumin utilizes a successful lipid-based drug delivery system, with some liposomal formulations having already received FDA approval. Owing to curcumin’s low water solubility and subsequent low systemic bioavailability, its encapsulation into liposomes (artificially-prepared vesicle composed of a lipid bilayer) greatly improves its ability to gain entry into the body by passing through the ‘glucoronidation barrier’ in the liver.
Exocrine pancreatic cancer is notorious for responding poorly to conventional treatment, with American Cancer Society statistics promising only a 14% 5-year survival rate in Stage IA cancers, spiraling down to only 1% for Stage IV types.
Moreover, even when chemotherapy, surgery and radiotherapy results in the successful debulking of the tumor, and the patient manages to survive past 5 years, recurrence is still common; this often occurs as a direct result of conventional treatment, which damages the immune system and enriches the treatment-resistance tumorigenic cancer stem cell population within the post-treatment cancer survivor’s body.
The new study was performed by researchers at the Department of Molecular Biology and Immunology, and Institute for Cancer Research, University of North Texas Health Science Center, Fort Worth, Texas. They determined the antitumor effects of a liposomal curcumin formulation against human pancreatic cancer cells through in vitro and xenograft studies, where the cells were implanted into mice to form tumors.
Read More: Here